BriaCell Therapeutics (NASDAQ:BCTX – Get Free Report) released its quarterly earnings data on Monday. The company reported ($2.33) earnings per share for the quarter, missing the consensus estimate of ($1.94) by ($0.39), Zacks reports.
BriaCell Therapeutics Stock Performance
Shares of NASDAQ:BCTX opened at $4.07 on Tuesday. The company has a market cap of $15.10 million, a P/E ratio of -0.31 and a beta of 1.71. BriaCell Therapeutics has a one year low of $3.00 and a one year high of $45.45. The business’s 50-day simple moving average is $4.73 and its 200 day simple moving average is $9.05.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright raised their target price on BriaCell Therapeutics from $15.00 to $32.00 and gave the company a “buy” rating in a report on Monday, February 3rd.
BriaCell Therapeutics Company Profile
BriaCell Therapeutics Corp., a clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted cell-based immunotherapy that is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer.
Featured Stories
- Five stocks we like better than BriaCell Therapeutics
- Investing in the High PE Growth Stocks
- Taiwan Semiconductor Valuation: How Realistic Is the Price?
- How to Evaluate a Stock Before Buying
- Microsoft’s AI Strategy Eases Analyst Concerns—Is It a Buy?
- 2 Fintech Stocks to Buy Now and 1 to Avoid
- CrowdStrike Stock Attracts Congressional Buyers—Time to Invest?
Receive News & Ratings for BriaCell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BriaCell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
